Person: Martínez Martínez, Carlos Hugo
Universidad Complutense de Madrid
Faculty / Institute
Now showing 1 - 3 of 3
PublicationA Validation Employing Convolutional Neural Network for the Radiographic Detection of Absence or Presence of Teeth(2021-03-12) Prados Privado, María; García Villalón, Javier; Blázquez Torres, Antonio; Martínez Martínez, Carlos Hugo; Ivorra, CarlosDental radiography plays an important role in clinical diagnosis, treatment and making decisions. In recent years, efforts have been made on developing techniques to detect objects in images. The aim of this study was to detect the absence or presence of teeth using an effective convolutional neural network, which reduces calculation times and has success rates greater than 95%. A total of 8000 dental panoramic images were collected. Each image and each tooth was categorized, independently and manually, by two experts with more than three years of experience in general dentistry. The neural network used consists of two main layers: object detection and classification, which is the support of the previous one. A Matterport Mask RCNN was employed in the object detection. A ResNet (Atrous Convolution) was employed in the classification layer. The neural model achieved a total loss of 0.76% (accuracy of 99.24%). The architecture used in the present study returned an almost perfect accuracy in detecting teeth on images from different devices and different pathologies and ages. PublicationAnalysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients(MDPI, 2022-11-15) Zekri Nechar, Khaoula; Barberán, José; Zamorano León, José J.; Durbán, María; Andrés Castillo, Alcira; Navarro Cuéllar, Carlos; López Farré, Antonio José; López de Andrés, Ana; Jiménez García, Rodrigo; Martínez Martínez, Carlos HugoBackground and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. PublicationLa aspirina modifica en los megacariocitos las propiedades pre-apoptóticas de las plaquetas de novo(Universidad Complutense de Madrid, 2021-08-19) Martínez Martínez, Carlos Hugo; López Farré, Antonio; Zamorano León, José JavierEl tratamiento crónico con dosis bajas de ácido acetilsalicílico (se utilizará en todo el texto indistintamente el término Aspirina o su abreviación ASA), entre 100-300 mg/día, es primera elección en la prevención de eventos vasculares trombóticos agudos. Sin embargo en, un número importante de pacientes tratados diariamente con ASA, sus plaquetas no son completamente inhibidas. Este efecto se conoce como síndrome de resistencia plaquetaria a la ASA. El síndrome plaquetario de resistencia a la ASA se calcula que ocurre en el 20% de la población general tratada con ASA y hasta en un 40% de población de pacientes diabéticos. Se ha especulado diferentes mecanismos implicados en el síndrome de resistencia plaquetaria a ASA entre los que se incluye la no adherencia al tratamiento, la administración previa de AINES, la existencia de una isoforma diferente de ciclooxigenasa, la ciclooxigenasa-2, en las plaquetas, la falta de capacidad de las plaquetas resistentes a ASA y/o de los leucocitos de los pacientes con plaquetas resistentes a ASA de generar óxido nítrico etc...